Translational Programs (2011 - 2022)
Translational Stem Cell Research and Therapy at DanStem is focused on the translation of promising basic research results into new strategies and targets for the development of new therapies for hematological cancer and diabetes. The aim is to strengthen these fields towards clinical application.
- Development of a safe and efficient therapy for diabetes based on human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), including development of scalable differentiation protocols for functional insulin-producing beta cells.
- Establishment of human iPSC-based in vitro models for inherited forms of diabetes.
- Identification and validation of novel targets for anti-cancer therapy.
- Strengthening both the short- and long-term research and clinical management of blood cancer.
Translational Research Programs
PanCryos: PanCryos is a spin out company arising from DanStem, aiming to develop a next generation stem cell derived allogenic cell therapy (PanINSULA™) for type 1 diabetes, based on novel IP in the differentiation of stem cells into mature beta cells and in the purification of pancreatic progenitor cells.
Porse Laboratory focuses on delineating gene regulatory networks in normal and malignant stem cells in order to understand how normal hematopoietic stem cells are distinct from their leukemic counterparts and to identify novel candidates for future drug development.. read more
Wennerberg Laboratory aims to discover novel personalized therapeutic strategies and define and understand the molecular mechanisms driving the cancers, their drug responses and mechanisms of resistance. read more
Grønbæk Laboratory aims to understand and target the progression from clonal cytopenia of undetermined significance (CCUS) to myelodysplastic syndrome (MDS) as well as the molecular aberrations underlying mantle cell lymphoma (MCL).
Helin Laboratory investigates the mechanisms that regulate cell-fate decisions in stem cells, differentiated cells as well as tumor cells with the aim of gaining new insights into the molecular mechanisms leading to cancer ... read more
Kyoung-Jae Won, aims to further our understanding of the genome by integrating large-scale genomic datasets and develop computational methods to exploit multi-dimensional genomic/epigenomic landscapes to understand cell-type specific or spatio-temporal gene regulation. read more
Weischenfeldt Group interested in the mutational mechanisms and clonal evolution of cancer, in particular mechanisms of complex structural variants and the impact on 3D chromatin organization.
Head of Translational Diabetes
Professor Henrik Semb